Randomized Controlled Trial of Zoledronic Acid plus Chemotherapy versus Chemotherapy Alone as Neoadjuvant Treatment of HER2-Negative Primary Breast Cancer (JONIE Study).

PLoS One · 2015 · PMC4669153 · PMID 26633806

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

not quite significantno p-value reported

Although not quite significant at the 0.05 level, with the relatively higher pCR rate, concomitant ZOL seems to show clinically beneficial antitumor effect on at least some of the breast cancer patients who receive neoadjuvant CT.

also in 653 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.